

# Ziva Cooper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1437643/publications.pdf>

Version: 2024-02-01

72  
papers

3,051  
citations

147801

31  
h-index

168389

53  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2769  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 155-165.   | 2.9 | 8         |
| 2  | Selective Changes in Medical Cannabis Use Early in the COVID-19 Pandemic: Findings from a Web-Based Sample of Adults in the United States. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 174-183.   | 2.9 | 7         |
| 3  | Changes in secondary substance use after the onset of the COVID-19 pandemic among people who use cannabis: Findings from a web-based sample of adults in the United States.. <i>Experimental and Clinical Psychopharmacology</i> , 2023, 31, 482-490. | 1.8 | 1         |
| 4  | A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 347-355.                    | 2.4 | 32        |
| 5  | Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 706-716.   | 2.9 | 16        |
| 6  | Changes in medical and non-medical cannabis use among United States adults before and during the COVID-19 pandemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 321-327.  | 2.1 | 11        |
| 7  | Drugs of Misuse: Focus on Vascular Dysfunction. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1364-1377.  | 1.7 | 12        |
| 8  | Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 517-527.  | 1.8 | 5         |
| 9  | Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. <i>Addiction Biology</i> , 2022, 27, .   | 2.6 | 4         |
| 10 | 5HT <sub>2C</sub> agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers. <i>Addiction Biology</i> , 2021, 26, e12993.   | 2.6 | 9         |
| 11 | Challenges for Clinical Cannabis and Cannabinoid Research in the United States. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 114-122.   | 2.1 | 21        |
| 12 | Motivational interviewing to treat substance use disorders in the emergency department: A scoping review. <i>American Journal of Emergency Medicine</i> , 2021, 51, 414-414.  | 1.6 | 2         |
| 13 | Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 137-146.   | 1.8 | 0         |
| 14 | A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 535-547.   | 2.1 | 13        |
| 15 | Sex-dependent effects of alcohol administration on the urge to use cannabis.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 689-695.  | 1.8 | 7         |
| 16 | Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173059.  | 2.9 | 28        |
| 17 | Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. <i>International Journal of Clinical Practice</i> , 2020, 75, e13871.   | 1.7 | 26        |
| 18 | Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications. <i>Alcohol and Alcoholism</i> , 2020, 55, 416-423.  | 1.6 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 580-595. | 2.1 | 11        |
| 20 | Cognitive function in aging cocaine smokers. <i>Journal of Psychopharmacology</i> , 2019, 33, 801-810.  | 4.0 | 6         |
| 21 | Necessity of addressing motivations for cannabis use to guide research. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 547-550.  | 2.1 | 1         |
| 22 | Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. <i>PLoS Medicine</i> , 2019, 16, e1002967.  | 8.4 | 56        |
| 23 | 2.10 CANNABIS AND OTHER SUBSTANCE USE, COMORBID PSYCHIATRIC DISORDERS, AND CHILDHOOD ADVERSITY IN AN OUTPATIENT CHILD AND ADOLESCENT PSYCHIATRY CLINIC. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, S174.                 | 0.5 | 0         |
| 24 | Cannabis legalization: progress in harm reduction approaches for substance use and misuse. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 707-712.   | 2.1 | 11        |
| 25 | Social motivational processing and interpersonal function in aging cocaine smokers. <i>Addiction Biology</i> , 2019, 24, 1044-1055.   | 2.6 | 7         |
| 26 | Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. <i>Addiction Biology</i> , 2019, 24, 765-776.  | 2.6 | 16        |
| 27 | Cannabis and Cannabinoid Intoxication and Toxicity. , 2019, , 103-111.  |     | 3         |
| 28 | Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. <i>Addiction Biology</i> , 2019, 24, 707-716.   | 2.6 | 20        |
| 29 | Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. <i>Neuropsychopharmacology</i> , 2018, 43, 2046-2055.  | 5.4 | 110       |
| 30 | Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. <i>Neuropharmacology</i> , 2018, 134, 92-100.   | 4.1 | 7         |
| 31 | Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. <i>Neuropsychopharmacology</i> , 2018, 43, 34-51.  | 5.4 | 223       |
| 32 | F259. Social Motivational Processing and Interpersonal Function in Aging Cocaine Smokers. <i>Biological Psychiatry</i> , 2018, 83, S339-S340.   | 1.3 | 0         |
| 33 | Cannabis and the Opioid Crisis. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 108-116.  | 2.9 | 10        |
| 34 | A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 155-159.   | 2.9 | 8         |
| 35 | Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2017, 178, 340-347.   | 3.2 | 15        |
| 36 | Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. <i>Current Psychiatry Reports</i> , 2016, 18, 52.   | 4.5 | 200       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. <i>Psychopharmacology</i> , 2016, 233, 2469-2478.  | 3.1 | 42        |
| 38 | Sex-dependent effects of cannabis-induced analgesia. <i>Drug and Alcohol Dependence</i> , 2016, 167, 112-120.   | 3.2 | 67        |
| 39 | Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. <i>Neuropsychopharmacology</i> , 2016, 41, 1974-1982.   | 5.4 | 160       |
| 40 | The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. <i>Addiction Biology</i> , 2016, 21, 895-903.   | 2.6 | 85        |
| 41 | Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. <i>Neuropsychopharmacology</i> , 2015, 40, 2489-2498.   | 5.4 | 55        |
| 42 | Investigation of sex-dependent effects of cannabis in daily cannabis smokers. <i>Drug and Alcohol Dependence</i> , 2014, 136, 85-91.  | 3.2 | 136       |
| 43 | Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. <i>Current Addiction Reports</i> , 2014, 1, 137-143.  | 3.4 | 53        |
| 44 | Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. <i>Addiction Biology</i> , 2013, 18, 872-881.   | 2.6 | 61        |
| 45 | A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. <i>Addiction Biology</i> , 2013, 18, 993-1002.   | 2.6 | 50        |
| 46 | Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers. <i>Neuropsychopharmacology</i> , 2013, 38, 1984-1992.  | 5.4 | 71        |
| 47 | Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse. <i>Neuropsychopharmacology</i> , 2013, 38, 1557-1565.  | 5.4 | 112       |
| 48 | Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking Status. <i>Biological Psychiatry</i> , 2013, 73, 242-248.   | 1.3 | 86        |
| 49 | Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. <i>Pain</i> , 2013, 154, 1442-1448. | 4.2 | 46        |
| 50 | Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques. <i>Hormones and Behavior</i> , 2013, 63, 105-113.   | 2.1 | 17        |
| 51 | Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. <i>Neuropsychopharmacology</i> , 2013, 38, 2427-2438.                                   | 5.4 | 49        |
| 52 | Medications for Treatment of Marijuana Dependence. , 2013, , 397-406.   |     | 0         |
| 53 | Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. <i>Behavioural Pharmacology</i> , 2013, 24, 504-516.                                   | 1.7 | 25        |
| 54 | Marijuana's dose-dependent effects in daily marijuana smokers.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 287-293.  | 1.8 | 44        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 169-178.   | 4.1 | 42        |
| 56 | Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers. <i>Behavioural Pharmacology</i> , 2012, 23, 271-279.  | 1.7 | 20        |
| 57 | Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health. <i>Addiction</i> , 2012, 107, 642-649.  | 3.3 | 4         |
| 58 | Oxycodone lengthens reproductions of suprasedond time intervals in human research volunteers. <i>Behavioural Pharmacology</i> , 2011, 22, 354-361.  | 1.7 | 5         |
| 59 | Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. <i>Psychopharmacology</i> , 2010, 208, 45-55.  | 3.1 | 47        |
| 60 | Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. <i>Psychopharmacology</i> , 2010, 211, 141-148.  | 3.1 | 51        |
| 61 | Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. <i>Psychopharmacology</i> , 2010, 211, 233-244.  | 3.1 | 71        |
| 62 | Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. <i>Psychopharmacology</i> , 2010, 212, 369-378.  | 3.1 | 27        |
| 63 | Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. <i>Addiction</i> , 2010, 105, 709-718.  | 3.3 | 94        |
| 64 | Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. <i>Drug and Alcohol Dependence</i> , 2010, 106, 219-229.   | 3.2 | 23        |
| 65 | A Bacterial Cocaine Esterase Protects Against Cocaine-Induced Epileptogenic Activity and Lethality. <i>Annals of Emergency Medicine</i> , 2009, 54, 409-420.  | 0.6 | 23        |
| 66 | Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. <i>International Review of Psychiatry</i> , 2009, 21, 104-112.   | 2.8 | 98        |
| 67 | Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. <i>Drug and Alcohol Dependence</i> , 2009, 103, 107-113.   | 3.2 | 155       |
| 68 | Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. <i>Addiction Biology</i> , 2008, 13, 188-195.  | 2.6 | 124       |
| 69 | Morphine Deprivation Increases Self-Administration of the Fast- and Short-Acting $\mu$ -Opioid Receptor Agonist Remifentanyl in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 920-929. | 2.5 | 55        |
| 70 | Cocaine Esterase: Interactions with Cocaine and Immune Responses in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 926-933.  | 2.5 | 41        |
| 71 | Rapid and Robust Protection against Cocaine-Induced Lethality in Rats by the Bacterial Cocaine Esterase. <i>Molecular Pharmacology</i> , 2006, 70, 1885-1891.   | 2.3 | 49        |
| 72 | Paradoxical Effects of Chronic Morphine Treatment on the Temperature and Pituitary-Adrenal Responses to Acute Restraint Stress: A Chronic Stress Paradigm. <i>Journal of Neuroendocrinology</i> , 2001, 13, 862-874.        | 2.6 | 55        |